FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy
October 16, 2024 6:06 AM EDTH.C. Wainwright analyst Emily Bodnar upgraded NovoCure Ltd. (NASDAQ: NVCR) from Neutral to Buy with a price target of $30.00.
The analyst comments "Optune Lua receives FDA approval with favorable label based on the LUNAR Phase 3 study. Yesterday after market close, Novocure announced that the FDA has approved Optune Lua for the treatment of metastatic NSCLC for use concurrently with PD-(L)1 inhibitors or docetaxel in patients who have progressed on or after a platinum based regimen. The approval was based on the Phase 3 LUNAR study which demonstrated that there was a 3.3... More
